The U.S. Food and Drug Administration (FDA) already declared that shortages of popular GLP-1 medications have ended, CNN reported. Those medications include semaglutide (Ozempic and Wegovy) and ...

Compounded vs non-compounded GLP-1 RA drug products are associated with an increased risk for adverse events such as nausea and diarrhea.

For adults with diabetes and obesity, GLP-1 RAs are associated with a reduced risk for obesity-related cancer compared with DPP-4 inhibitors.

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the ...

Novo Nordisk NVO shares have gained 13.9% in the past month. Several factors related to the company’s pipeline, regulatory updates and sector-specific developments have contributed to the much-awaited ...

He turned to an online telehealth provider, Henry Meds, to get a compounded GLP-1 instead. He switched to tirzepatide, the active ingredient in Eli Lilly’s Zepbound, at a dosage that cost $450 a ...

Participants are individuals with obesity who have not yet taken GLP-1 drugs, are initiated on tirzepatide at the time of enrollment, and treated with the drug to achieve at least 15% total body ...

Getty Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study. According to research published May 11 in the New England ...

But tirzepatide targets two such hormones, known as GLP-1 and GIP, while semaglutide targets GLP-1 alone, said Dr. Louis Aronne, director of the Comprehensive Weight Control Center at Weill Cornell ...

This comprehensive review explores MEDVi, a leading telehealth provider offering compounded GLP-1 weight loss solutions like Semaglutide and Tirzepatide in both injection and tablet form.